256 related articles for article (PubMed ID: 28812531)
1. Prolactinoma in a Dog.
Cosio C; Sartori E; Garatti M; Luccardini L; Grinwis GCM; Kooistra HS; Fracassi F
Vet Pathol; 2017 Nov; 54(6):972-976. PubMed ID: 28812531
[TBL] [Abstract][Full Text] [Related]
2. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
3. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
4. Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma.
Eli IM; Raheja A; Corn HJ; Simmons DL; Palmer CA; Couldwell WT
World Neurosurg; 2016 Nov; 95():622.e1-622.e5. PubMed ID: 27521731
[TBL] [Abstract][Full Text] [Related]
5. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
6. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
7. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
[No Abstract] [Full Text] [Related]
8. Prolactinoma - which patients react favorably to cabergoline medication?
Karatas S; Hacioglu Y; Rakicioglu T
Endocr Regul; 2022 Oct; 56(4):279-283. PubMed ID: 36270341
[No Abstract] [Full Text] [Related]
9. Cabergoline treatment in a case of macroprolactinoma after delivery.
Falsetti L
Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
[TBL] [Abstract][Full Text] [Related]
10. Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.
Yano S; Hide T; Uekawa K; Honda Y; Mikami Y; Kuratsu JI
World Neurosurg; 2016 Nov; 95():620.e17-620.e22. PubMed ID: 27535625
[TBL] [Abstract][Full Text] [Related]
11. Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration.
Melis GB; Gambacciani M; Paoletti AM; Mais V; Sghedoni D; Fioretti P
Fertil Steril; 1989 Sep; 52(3):412-5. PubMed ID: 2570719
[TBL] [Abstract][Full Text] [Related]
12. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
[TBL] [Abstract][Full Text] [Related]
13. The cabergoline-resistant prolactinoma patient: new challenges.
Molitch ME
J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
[No Abstract] [Full Text] [Related]
14. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
[TBL] [Abstract][Full Text] [Related]
15. Pituitary apoplexy associated with cabergoline therapy.
Chng E; Dalan R
J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
[TBL] [Abstract][Full Text] [Related]
16. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
17. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Cackett P; Eunson G; Bath L; Mulvihill A
Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
[TBL] [Abstract][Full Text] [Related]
18. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
19. [Prolactinoma treatment status in the cabergoline era].
Watanabe S; Takano S; Akutsu H; Sato H; Matsumura A
No Shinkei Geka; 2011 Nov; 39(11):1045-54. PubMed ID: 22036815
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma.
Heimburger C; Bund C; Addeo P; Goichot B; Imperiale A
Clin Nucl Med; 2018 Sep; 43(9):e324-e325. PubMed ID: 30052596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]